Loading...
Bortezomib Against Refractory Antibody-Mediated Rejection After ABO-Incompatible Living-Donor Liver Transplantation: Dramatic Effect in Acute-Phase?
Antibody-mediated rejection (AMR) is a refractory rejection after donor-specific antibody-positive or ABO blood-type incompatible (ABOi) organ transplantation. Rituximab dramatically improved the outcome of ABOi living-donor liver transplantation (LDLT); however, an effective treatment for posttrans...
Na minha lista:
| Udgivet i: | Transplant Direct |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Wolters Kluwer Health
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6791599/ https://ncbi.nlm.nih.gov/pubmed/31723586 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/TXD.0000000000000932 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|